MoonLake Immunotherapeutics
MoonLake Immunotherapeutics (MLTX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · MLTX · as of Mar 31, 2025
Ownership Breakdown
150
Institutional Holders
▲ 24 vs Q4
$2.33B
Total Inst. Value
▼ $1.09B vs Q4
73.62M
Shares Outstanding
freeFloat 85.86%
59.72M
13F Shares Held
▼ 3.52M vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
MLTX largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BVF INC/IL pharmaceutical preparations | 19.75M | 31.24% | 31.24% | $771.68B | May 15, 2025 | — held |
CORMORANT ASSET MANAGEMENT, LP pharmaceutical preparations | 8.49M | 13.43% | 13.43% | $331.87B | May 15, 2025 | — held |
FMR LLC pharmaceutical preparations | 6.33M | 10.01% | 10.01% | $247.20B | May 12, 2025 | ▼ 14.4K |
PRICE T ROWE ASSOCIATES INC /MD/ pharmaceutical preparations | 2.97M | 4.70% | 4.70% | $116.19B | May 14, 2025 | ▼ 369.8K |
AVORO CAPITAL ADVISORS LLC pharmaceutical preparations | 2.77M | 4.38% | 4.38% | $108.23B | May 15, 2025 | — held |
CITADEL ADVISORS LLC pharmaceutical preparations | 1.48M | 2.34% | 2.34% | $57.77B | May 15, 2025 | ▼ 708.2K |
WESTFIELD CAPITAL MANAGEMENT CO LP pharmaceutical preparations | 1.43M | 2.27% | 2.27% | $56.06B | May 9, 2025 | ▲ 123.2K |
GOLDMAN SACHS GROUP INC pharmaceutical preparations | 1.29M | 2.04% | 2.04% | $50.50B | Jun 27, 2025 | ▼ 382.1K |
FEDERATED HERMES, INC. pharmaceutical preparations | 1.27M | 2.01% | 2.01% | $49.59B | May 8, 2025 | ▼ 10.7K |
POLAR CAPITAL HOLDINGS PLC pharmaceutical preparations | 1.10M | 1.74% | 1.74% | $42.98B | May 15, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
13
Increased
+837.5K shares9
New Positions
first time holders21
Decreased
−5.02M shares0
Sold Out
fully exitedNet shares change (top 50)
4.18M
+837.5K / −5.02M
Net new holders
+1
9 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
MLTX insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
6
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Bodenstedt Matthias Chief Financial Officer | May 11, 2026 | Sale | 13,653 | $20.02 | $273.3K | 1.17M | Form 4 ↗ |
Bodenstedt Matthias Chief Financial Officer | Apr 14, 2026 | Sale | 2,426 | $19.56 | $47.5K | 1.19M | Form 4 ↗ |
Santos da Silva Jorge Chief Executive Officer | Apr 10, 2026 | Sale | 98,127 | $18.41 | $1.81M | 2.98M | Form 4 ↗ |
Santos da Silva Jorge Chief Executive Officer | Apr 13, 2026 | Sale | 51,873 | $18.23 | $945.6K | 2.92M | Form 4 ↗ |
Bodenstedt Matthias Chief Financial Officer | Apr 9, 2026 | Sale | 85,870 | $18.94 | $1.63M | 1.19M | Form 4 ↗ |
Bodenstedt Matthias Chief Financial Officer | Apr 10, 2026 | Sale | 1,925 | $19.51 | $37.6K | 1.19M | Form 4 ↗ |
BVF PARTNERS L P/IL
| Mar 31, 2026 | Sale | 1,932,354 | $16.79 | $32.44M | 8.30M | Form 4 ↗ |
BVF PARTNERS L P/IL
| Mar 31, 2026 | Sale | 1,569,116 | $16.79 | $26.35M | 6.60M | Form 4 ↗ |
BVF PARTNERS L P/IL
| Mar 31, 2026 | Sale | 248,530 | $16.79 | $4.17M | 1.04M | Form 4 ↗ |
Bodenstedt Matthias Chief Financial Officer | Jan 7, 2026 | Award | 354,296 | — | — | 1.28M | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
MoonLake Immunotherapeutics (MLTX) is primarily owned by institutional investors, who hold approximately 81.1% of total shares outstanding. Company insiders own approximately 14.14%, while retail and public investors account for the remaining 4.73%.
The largest institutional shareholder of MoonLake Immunotherapeutics is BVF INC/IL, holding approximately 19.75 million shares — equal to 31.24% of outstanding shares — as of March 31, 2025.
A total of 150 institutional investors currently hold MLTX stock, with a combined institutional value of approximately $2.33 billion as of the most recent 13F filing period.
Frequently asked questions
MLTX ownershipMoonLake Immunotherapeutics (MLTX) is primarily owned by institutional investors, who hold approximately 81.1% of shares. The largest shareholder is BVF INC/IL with a 31.24% stake. Company insiders hold 14.14%. Data sourced from SEC Form 13F as of March 31, 2025.